Passage Bio has provided financial information for its proposed combination with Remix Therapeutics, after Passage Bio stockholders approved merger-related proposals at a November 5 meeting. The materials include Remix’s interim financial statements and unaudited pro forma figures for Passage Bio, Remix and the combined company.
The merger has not been described as completed. Under the agreement, Remix would become a wholly owned Passage Bio subsidiary through a two-step merger. Completion remains subject to conditions, including any required regulatory clearances.
Key details
- Merger structure: Passage Bio’s wholly owned merger subsidiary would merge into Remix, with Remix surviving as a Passage Bio subsidiary. Immediately afterward, Remix would merge into a second wholly owned Passage Bio subsidiary, which would survive.
- Stockholder vote: Passage Bio stockholders approved proposals related to the merger at the November 5 special meeting. The agreement was signed September 2 and amended October 5.
- Financial information provided: The materials include Remix’s unaudited interim financial statements as of September 30, 2026, and for the nine months ended September 30, 2026 and 2025.
- Combined-company figures: Unaudited pro forma information covers Passage Bio, Remix and the combined company as of and for the nine months ended September 30, 2026, and for the year ended December 31, 2025. The figures rely on assumptions and estimates; they do not represent actual results after a completed merger or a forecast of future performance.
- Completion uncertainties: The companies identify possible delays or failure to close, including if required regulatory clearances are not obtained. They also cite integration challenges, the possibility that expected benefits may not be realized, and the combined company’s potential need for additional funding.
The new materials provide a financial view of Remix and an illustrative view of the proposed combination. They do not, by themselves, indicate that the merger has closed or establish what the combined company’s actual future results will be.
